Lec13 cells, a variant Chinese hamster ovary cell line, were used to produce human IgG1 that were deficient in fucose attached to the Asn 297 -linked carbohydrate but were otherwise similar to that found in IgG1 produced in normal Chinese hamster ovary cell lines and from human serum. Lack of fucose on the IgG1 had no effect on binding to human Fc␥RI, C1q, or the neonatal Fc receptor. Although no change in affinity was found for the His 131 polymorphic form of human Fc␥RIIA, a slight improvement in binding was evident for Fc␥RIIB and the Arg 131 Fc␥RIIA polymorphic form. In contrast, binding of the fucose-deficient IgG1 to human Fc␥RIIIA was improved up to 50-fold. Antibody-dependent cellular cytotoxicity assays using purified peripheral blood monocytes or natural killer cells from several donors showed enhanced cytotoxicity, especially evident at lower antibody concentrations. When combined with an IgG1 Fc protein variant that exhibited enhanced antibody-dependent cellular cytotoxicity, the lack of fucose was synergistic.
The nature and importance of the conserved, Asn 297 -linked carbohydrate in influencing immunoglobulin G effector functions has long been recognized (1) (2) (3) (4) . Variations in composition of the carbohydrate have been shown to affect the affinity of IgG for the three classes of Fc␥R (3, 4) (Fc␥RI (CD64), Fc␥RII (CD32), and Fc␥RIII (CD16)) that link IgG antibody-mediated immune responses with cellular effector functions (5-7). Carbohydrate composition also influences the activity of IgG in the classical pathway of complement activation, which is initiated by IgG1 binding to C1q (3, 4, 8) and to mannose-binding protein, which structurally resembles C1q (9 -11) . The role of carbohydrate in the clearance rate of IgG remains unclear. Binding of aglycosyl IgG to the neonatal Fc receptor (FcRn) 1 appears unperturbed (12) (13) (14) ; however, in some studies, glycosylated and aglycosyl-matched mAb show no appreciable difference in clearance rate in mice (13, 15, 16) , whereas in other studies differences have been detected (15) (16) (17) . Clearance of mAb may also be affected by variation in galactosylation through binding of agalactosyl IgG to mannose-binding protein or mannose receptors (10, 11) .
For IgG from either serum or produced ex vivo in hybridomas or engineered cells, the IgG are heterogeneous with respect to the Asn 297 -linked carbohydrate (3, 4, 18, 19) . For human IgG the core oligosaccharide normally consists of Asn 297 -N␦2-GlcNAc(fucose)-GlcNAc-mannose-(mannose-GlcNAc) 2 (Fig. 1) . Variation among individual IgG includes attachment of galactose and/or galactose-sialic acid at one or both of the terminal GlcNAc and/or attachment of a third GlcNAc arm (bisecting GlcNAc). The presence or absence of terminal galatose or sialic acid residues affects IgG function (11, 20 -24) , and attachment of a third arm to the carbohydrate via bisecting GlcNAc has been reported to improve antibody-dependent cellular cytotoxicity (ADCC) (25, 26) . A connection between IgG glycosylation and some human diseases has been shown (e.g. the level of galactosylation appears correlated with rheumatoid arthritis) (27) .
Several recombinant monoclonal antibodies (mAbs) are being used as human therapeutics (28) . Some of these (e.g. mAbs that bind to a receptor or soluble ligand and thereby block ligand-receptor interaction) may function without utilizing antibody effector mechanisms. Abrogating immune system recruitment for these mAbs can be achieved by altering IgG residues in the lower hinge region (29, 30) , using IgG2 or IgG4 subclasses, which are relatively less efficient in effector function, or using F(ab) or F(abЈ)2 fragments (although these may have undesirable clearance rates). Other mAbs may need to recruit the immune system to kill the target cell (31) (32) (33) (34) . In those circumstances where recruitment of immune effector cells is desirable for therapeutic mAb efficacy, engineering the IgG Fc portion to improve effector function (via improved binding to IgG receptors and/or complement) could be a valuable enhancement to antibody therapeutics. Currently, methods that improve the immune system recruitment include bispecific antibodies in which one arm of the antibody binds to an IgG receptor (35) , IgG-cytokine fusion proteins (36) , alteration of the IgG Fc sequence for improved binding to Fc␥R (12) , and optimization of the Asn 297 -linked carbohydrate (25, 26, 37) . To evaluate the role of fucosylated oligosaccharide in IgG function, the Lec13 cell line (38) was utilized to express human IgG1. This Chinese hamster ovary (CHO) cell line is deficient in its ability to add fucose but provided IgG with oligosaccharide that was otherwise similar to that found in normal CHO cell lines and from human serum (18, 19, 39) . The resultant IgGs were used to evaluate the effect of fucosylated carbohydrate on antibody effector functions, including binding to hu-man Fc␥R, human C1q, human FcRn, and ADCC using human effector cells.
EXPERIMENTAL PROCEDURES
cDNA Constructs for Stable Cell Lines-The heavy and light chains of Hu4D5 (40) and HuE27 (41) were subcloned into a previously described mammalian cell expression vector (42) with the modification of a puromycin site fused 5Ј to the dihydrofolate reductase (DHFR) site to form a fusion gene. Puromycin is used as a selective marker in DHFR(ϩ) cells such as the Lec13 cells and the DHFR site was retained for methotrexate amplification of the stable cell line.
Transfection and Culturing of Lec13 and Wild-type CHO Cells-The CHO cell line Pro-Lec13.6a (Lec13), was obtained from Professor Pamela Stanley of Albert Einstein College of Medicine of Yeshiva University. Parental lines were Pro Ϫ (proline auxotroph) and GAT Ϫ (glycine, adenosine, thymidine auxotroph). The CHO-DP12 cell line used for wild-type antibodies is a derivative of the CHO-K1 cell line (ATCC number CCL-61) which is DHFR-deficient and has a reduced requirement for insulin. Cell lines were transfected with cDNA using the Superfect method (Qiagen, Valencia, CA). Selection of stably transfected Lec13 cells expressing mAbs was performed using puromycin dihydrochloride (Calbiochem) at 10 g/ml in growth medium containing minimal essential medium-␣ medium with L-glutamine, ribonucleosides, and deoxyribonucleosides (Invitrogen), supplemented with 10% inactivated fetal bovine serum (Invitrogen), 10 mM HEPES, and 1ϫ penicillin/streptomycin (Invitrogen). Selection of wild-type CHO-DP12 cells was performed in growth medium containing Ham's F-12 without GHT (glycine, hypoxanthine, thymidine), low glucose Dulbecco's modified Eagle's medium without glycine with NaHCO 3 , supplemented with 5% dialyzed fetal bovine serum (Invitrogen), 10 mM HEPES, 2 mM L-glutamine, and penicillin/streptomycin. Colonies formed within 2-3 weeks and were pooled for expansion. The pools were seeded initially at 3 ϫ 10 6 cells/10-cm plate for small batch protein expression. The cells were converted to serum-free medium once they grew to 90 -95% confluence, and after 3-5 days cell supernatants were collected and quantified for mAb expression using both an anti-IgG-Fc and an anti-intact IgG ELISA.
Protein Expression and Analysis-For each batch of mAb, Lec13 and wild-type CHO cells were seeded at ϳ8 ϫ 10 6 cells/15-cm plate 1 day prior to converting to PSO4 (43) production medium, supplemented with 10 mg/liter recombinant human insulin and 1 mg/liter trace elements (43) . Cells remained in serum-free production medium for 3-5 days. Supernatants were collected and clarified by centrifugation in 150-ml conical tubes to remove cells and debris. The protease inhibitors phenylmethylsulfonyl fluoride and aprotinin (Sigma) were added, and the supernatants were concentrated 5-fold on stirred cells using MWCO30 filters (Amicon, Beverly, MA) prior to immediate purification using protein A chromatography (Amersham Biosciences). All proteins were buffer-exchanged into phosphate-buffered saline using Centriprep-30 concentrators (Amicon) and analyzed by SDS-polyacrylamide gel electrophoresis. Protein concentrations were determined using A 280 and verified using amino acid composition analysis. On average, the Lec13 cells generated 10 g of mAb per 15-cm plate; expression in control CHO cells for all antibodies was 4 -5 times higher than in the Lec13 cells. Antibodies generated from CHO-DP12 grown on plates will be denoted as CHO-P.
CHO-DP12 cells were also grown in spinner flasks. Cells were seeded at 6 ϫ 10 5 cells/ml and grown at 37°C for 2 days. On the third day, the temperature was shifted to 33°C, and the cells were allowed to grow until viability dropped to 70% due to the pH dropping to ϳ6.5. Antibodies derived from CHO-DP12 cells grown in spinner flasks will be denoted as CHO-S.
Matrix-assisted laser desorption/ionization time-of-flight mass spectral analysis was used to characterize the Asn 297 -linked oligosaccharides on the mAbs following a previously described protocol (12, 44) .
Binding of Antibodies to Fc␥R, FcRn, and C1q: Antibody-dependent Cell Cytotoxicity Assays-Assays for measuring binding of monomeric IgG1 to Fc␥RI and FcRn (12) , binding of trimeric IgG1 to Fc␥RII and Fc␥RIII (12) , and binding of dimeric IgG1 to Fc␥R (45) and ADCC assays with natural killer (NK) cells and peripheral blood monocytes (PBMC) of Fc␥RIIIA genotyped donors have been described previously (12) . The assay used to measure binding to human C1q has also been previously described (46) .
Immunofluorescence staining of purified NK cells from an Fc␥RIIIA(Phe 158 /Phe 158 ) donor was performed using Hu4D5 variants. NK cells were purified by negative selection and gated with phycoerythrin-conjugated anti-CD56 and fluorescein isothiocyanate-conjugated anti-CD16 (Pharmingen, San Diego, CA). Cells were adjusted to 2 ϫ 10 6 /ml and incubated with 2 g/ml Hu4D5 variants for 30 min in ice-cold phosphate-buffered saline containing 0.1% bovine serum albumin, 0.01% sodium azide. Cells were then washed, and antibody binding was detected by incubating with fluorescein isothiocyanate-conjugated F(abЈ) 2 goat anti-human IgG for 30 min.
RESULTS

Binding of mAbs to Human FcR-Anti-HER2
Hu4D5 mAb (40) expressed in stably transfected Lec13 cells consistently had about 10% fucosylated carbohydrate (Table I ). In contrast, Hu4D5 mAbs from stably transfected CHO-DP12 cells cultured in spinner flasks (CHO-S) or plates (CHO-P) showed about 98% fucosylated carbohydrate. The variation in galactosylation for the Lec13 mAbs was similar to that found for CHO-S mAbs (as opposed to CHO-P) (Table I) ; hence, CHO-S mAbs were used as reference in the binding assays.
Monomeric Hu4D5-Lec13 IgG1 bound to human Fc␥RI equivalent to binding of Hu4D5-CHO-S (Table II) . The EC 50 values (ϳ0.1 g/ml) correspond to an affinity constant of 0.7 nM, at the lower end of the range of previously determined values (6, 7) . In contrast to Fc␥RI, IgG binding to the low affinity Fc␥R (Fc␥RII and Fc␥RIII) required the formation of dimers (Hu4D5 and HuE27) or trimers (HuE27) (12, 47) to detect binding. For Fc␥RIIA there are naturally occurring allotypes at position 131 that result in different binding avidities for IgG2 (48, 49) . Binding of Hu4D5-Lec13 dimers to the Fc␥RIIA(Arg 131 ) polymorphic form and to Fc␥RIIB exhibited only a slight improvement compared with Hu4D5-CHO-S (Fig.  2, A and B) . Lack of fucose did not affect binding to the Fc␥RIIA(His 131 ) polymorphic form (Fig. 2C ). Note that in contrast to Fc␥RI and Fc␥RIIIA, binding of the antibodies to Fc␥RIIA and Fc␥RIIB did not reach a plateau at the highest concentration used (10 g/ml) (Fig. 2, A and B) ; hence, EC 50 values could not be calculated. At concentrations above 10 g/ml, aggregation of mAb was problematic. Human Fc␥RIIIA has naturally occurring allotypes at position 48 Table II ). HuE27-Lec13 dimers also exhibited a 50-fold enhancement in binding to both polymorphic forms of Fc␥RIIIA compared with HuE27 CHO-P ( Fig. 4A ; Table II ). The binding of HuE27 expressed in HEK293 cells was intermediate to HuE27-Lec13 and CHO-P ( Fig. 4A ; Table II) and correlates to the percentage of HuE27 mAb without fucose: CHO-P, 2%; HEK293, 16%; Lec13, 78% (Table I ). The EC 50 values for Hu4D5-Lec13 and HuE27-Lec13 (as dimers) were 0.24 and 0.19 g/ml, respectively, for Fc␥RIIIA(Phe 158 ) and 0.07 and 0.05 g/ml, respectively, for Fc␥RIIIA(Val 158 ) ( Table  II) , showing that the binding of the Lec13 antibodies was independent of antibody specificity.
In a previous study of the effect of protein sequence variants of human IgG1 on binding to human Fc␥R, an S298A/E333A/ K334A-IgG1 variant showed improved binding to Fc␥RIIIA as well as more potent cytotoxicity in ADCC assays (12) . Expressing Hu4D5 S298A/E333A/K334A-IgG1 in Lec13 cells added fucose deficiency to this protein-sequence variant (Table I) In addition to dimers, complexes consisting of three anti-IgE HuE27 and three IgE were used to test binding to Fc␥RIIIA; these complexes are trimeric in anti-IgE HuE27 (12) . Binding to Fc␥RIIIA by the trimeric complexes was stronger than for the corresponding dimeric complexes (Fig. 4, A and B ; Table II) , suggesting an appreciable avidity component. The avidity resulted in a smaller improvement in binding to Fc␥RIIIA(Phe 158 ) for trimeric HuE27-Lec13, only 13-fold, compared with 53-fold for dimeric HuE27. In a previous study, the improvement in binding of trimeric HuE27 S298A/E333A/ K334A-IgG1 variant to Fc␥RIIIA(Phe 158 ) and Fc␥RIIIA(Val 158 ) was 2-and 1.1-fold, respectively; whereas the improvement in binding was small, the effect on ADCC was significant (12) . In the current study, the trimeric complex of HuE27 S298A/ E333A/K334A-IgG1 showed improved binding to both Fc␥RIIIA polymorphic forms in line with the values from the previous study (Fig. 4 , B and C; Table II ).
The improved binding of fucose-deficient IgG1 to Fc␥RIIIA was confirmed with Fc␥RIIIA(Phe 158 ) full-length ␣-chain coexpressed with ␥-chain on CHO cells ( Fig. 5 ; Table II) . As for the ␣-chain fusion protein alone in ELISA format, fucose deficiency was synergistic with the S298A/E333A/K334A-IgG1 variant.
Binding of the native and fucose-deficient IgG1 to murine Fc␥RII and Fc␥RIII was also evaluated. As trimeric complexes, the fucose-deficient HuE27 showed slightly reduced binding to both receptors compared with fucosylated HuE27 (data not shown). The major histocompatibility complex class I-like neonatal Fc receptor (FcRn) is structurally unrelated to the Fc␥R (52) and has been proposed to be involved in a number of biological processes including clearance rate of IgG (53). Bind- Gal0  Gal1  Gal2  Total  Gal0  Gal1  Gal2  Total   Hu4D5  CHO-S  1  2  0  0  3  50  42  6  98  CHO-P  0  2  0  0  2  70  25  3  98 Lec (12) . For Lec-X and Lec-AAA-X, X represents independently expressed lots of IgG.
b Values are percentage of total oligosaccharide. Glycoforms were determined by matrix-assisted laser desorption/ionization time-of-flight mass spectral analysis following a previously described protocol (12, 44) . Man, incompletely processed, hypermannosylated oligosaccharides containing 5-8 mannose units (19) . Gal0, Gal1, Gal2 are oligosaccharides with no (agalactosyl), one (monogalactosyl), or two (digalactosyl) galactose residues covalently linked to the terminal GlcNAc residues (see Fig. 1 ). Mean Ϯ S.D. is provided for six independently expressed lots of Hu4D5-Lec13 (A-E), three independently expressed lots of Hu4D5 Lec13-AAA (A-C), and three independently expressed lots of HuE27-HEK293. None of the mAbs contained measurable triantennary oligosaccharide (bisecting GlcNAc), and sialylated oligosaccharide was less than 6% of total oligosaccharide. ing of nonfucosylated and fucosylated IgG1 to FcRn was equivalent (ratio of 0.98 at 5 g/ml) (data not shown).
C1q Binding-Binding of C1q to antibodies is the first step in the classical pathway of complement activation (8) . The nature of the carbohydrate on the IgG has been shown to influence its interaction with C1q (3, 4, 22, 24) . However, the lack of fucose did not affect the ability of Hu4D5 to interact with human C1q (data not shown).
ADCC-The effect of fucosylated carbohydrate on ADCC was evaluated using Hu4D5-Lec13 IgG1 on the human breast cancer cell line SK-BR-3 (54 Fig. 6 , A and B. For all donors studied, the fucose-deficient IgG1 exhibited significant improvement in ADCC compared with IgG1 with fucose, especially at the lower antibody concentrations (Fig. 6) .
To verify that the combination of fucose deficiency and pro- (12) .
b Two independent lots of Hu4D5-Lec13 (A and B) used with four assays for lot A and five assays for lot B.
c Four independent lots of Hu4D5-Lec13 (A, B, C, and D) used with three assays per lot; three independent lots of Hu4D5-Lec13-AAA (A, B, and C) used with 1-3 assays per lot.
Three independent lots of Hu4D5-Lec13 (D, E, and F) used with three or four assays per lot; two independent lots of Hu4D5-Lec13-AAA (B and C) used with three assays per lot. tein sequence variant exhibited a synergistic effect, as seen in the ELISA and cell binding assays (Figs. 3-5) , immunofluorescence staining and ADCC assays were performed comparing native Hu4D5 and S298A/E333A/K334A-IgG1 variant with and without fucose against NK cells from two Fc␥RIIIA(Phe 158 / Phe 158 ) donors. The intensity of staining showed the pattern: Hu4D5 S298A/E333A/K334A-IgG1 Lec13 Ͼ Hu4D5 Lec13 Ͼ Hu4D5 CHO-S (Fig. 7A) . For the ADCC assays, SK-BR-3 cells were opsonized with 1 ng/ml mAb, and NK cells were used as effector cells. Both donors showed similar results; the fucose-deficient S298A/E333A/K334A-IgG1 was more potent than either fucose-deficient Hu4D5 or fucosylated S298A/ E333A/K334A-IgG1 (Fig. 7B) and correlated with the immunofluorescence staining.
DISCUSSION
Although the presence of carbohydrate is necessary for binding to Fc␥RI (12, 55) , the equivalent binding of IgG1 regardless of differences in fucose content (Lec13 versus CHO-S) or galactose content (CHO-P versus CHO-S) suggests that IgG1 binding to Fc␥RI is insensitive to the presence of these moieties on the carbohydrate. The effect of galactosylation on binding of IgG to human Fc␥RI has been previously studied (11, (22) (23) (24) , and review of the data suggests that if galactosylation affects binding to Fc␥RI, it is subtle and may be isotype-dependent (11) .
The small improvement in binding of fucose-deficient IgG1 to both Fc␥RIIA(Arg 131 ) and Fc␥RIIB, each having arginine at position 131, versus no effect on Fc␥RIIA(His 131 ) suggests that the fucose may either directly interact with the Fc␥R residue at position 131 or alter the IgG1 conformation so as to effect a subtle, negative influence on binding when arginine is present at Fc␥R position 131. As with Fc␥RI, the IgG1 galactose content did not seem to affect binding to Fc␥RII.
In contrast to the Fc␥RII class of receptors, lack of fucose effected a significant improvement in binding of IgG1 to Fc␥RIIIA. The absence of fucose not only increased binding of native IgG1 to Fc␥RIIIA but also augmented binding of the S298A/E333A/K334A-IgG1 variant. For both protein and carbohydrate variants of HuE27 (i.e. S298A/E333A/K334A-IgG1 and Lec13-derived), the improvement in binding of the trimeric complex was much smaller than that observed for the dimeric complex. For example, binding to Fc␥RIIIA(Phe 158 ) by HuE27-Lec13 (21% fucosylated) showed a 53-fold improvement compared with HuE27-CHO-P (98% fucosylated) when in dimeric form but only a 13-fold improvement when in the trimeric form (Table II) . This may result from the avidity effect evident when comparing binding of the dimeric and trimeric complexes (Fig.  4, A and B) and suggests that as the size of the immune complex is increased, the fucose effect diminishes.
Comparison of the carbohydrate found on native IgG1 for the Hu4D5 Lec13-produced and CHO-S-produced antibodies showed no appreciable differences in the extent of galactosylation, and hence the difference in binding can be attributed solely to the presence/absence of fucose. However, for the S298A/E333A/K334A IgG1 variant, the Lec13-produced and HEK293-produced antibodies also showed variation in galactosylation. While this complicates the interpretation of the data, the combination of protein sequence variation and lack of fucose was synergistic in binding to recombinant Fc␥RIIIA, native Fc␥RIIIA expressed on transfected CHO cells or on purified NK cells, and in the ADCC activity of Fc␥RIIIA-expressing NK and PBMC cells.
A previous study of protein sequence variants of human IgG1 found that alanine (and other) substitutions at some Fc posi- tions could reduce or improve binding to Fc␥R as well as enhance ADCC (12) . Interestingly, some of these substitutions were not near the interaction interface found in crystal structures of human IgG Fc-human Fc␥RIIIA complex (12, 56, 57) . For example, of the three alanine substitutions S298A/E333A/ K334A used in this study, only Ser 298 is at the Fc/Fc␥RIIIA interface in the crystal structures. Likewise, in the co-crystal structures, neither of the fucose residues on the two Fc heavy chains interact with Fc␥RIIIA. Inspection of crystal structures of human and rodent Fc or IgG shows that the fucose can adopt varying conformations and exhibits high B-factors (56 -60) , suggesting a high degree of mobility. Although the presence or absence of fucose definitely affects the interaction of an IgG with Fc␥RIIIA (and, to a lesser extent, Fc␥RIIA(Arg 131 ) and Fc␥RIIB), the current study cannot discern whether this is due to direct interaction of the fucose with receptor or to a conformational influence on the IgG itself.
Improved binding to Fc␥RIIIA translated into improved ADCC in vitro. Notably, for all donors the enhancement in cytotoxicity was more apparent as the concentration of antibody was reduced. This may reflect the larger improvement in binding seen for dimers compared with that for trimers (i.e. fucose-deficient IgG1 may require fewer mAbs on the surface of the target cell in order to effect binding/activation of an effector cell). If this is the case, it suggests that for therapeutic antibodies that utilize ADCC, nonfucosylated antibody could conceivably be given at lower doses to effect an equivalent cell kill as higher doses of fucosylated antibody.
In addition to the human Fc␥R, the influence of fucose on binding to C1q and FcRn were also investigated. Previous studies have shown that differences in IgG glycosylation can affect C1q binding, although the results of this study show that the presence/absence of fucose had no discernible effect. Likewise, the presence or absence of fucose did not affect IgG1 binding to FcRn. This is not surprising, since aglycosylated IgG1 binds this receptor similarly to glycosylated IgG1 (12) (13) (14) .
Rothman et al. (61) tested the ADCC function of monoclonal murine IgG purified from hybridomas treated with glycosidase inhibitors that acted at different stages in the carbohydrate processing pathway. Treatment with castanospermine, which inhibits removal of glucose residues from the nascent oligosaccharide (62), generated IgG that showed enhanced ADCC mediated by NK cells, which express only Fc␥RIIIA, but not by other types of effector cells such as monocytes. Lectin-binding analysis suggested that the castanospermine-treated IgG lacked fucose (61); however, the IgG resulting from such treatment probably had other carbohydrate structure, such as hypermannosylation as well as terminal glucose residues (4, 63, 64), not routinely found on IgG secreted from nontreated cells or from human serum. In the current study, Lec13 cells were utilized to produce fucose-deficient IgG1. Other than the lack of fucose, the oligosaccharide on the IgG1 was similar to that found in normal CHO cell lines and from human serum (18, 19, 39) and did not suffer from the hypermannosylation or hyperglucosylation resulting from the use of castanospermine. The improvement in Fc␥RIII binding and ADCC by the fucosedeficient IgG1 suggests that it is possible to generate monoclonal antibody with otherwise normal oligosaccharide that would have enhanced effector function.
Normal CHO and HEK293 cells add fucose to IgG oligosaccharide to a high degree (80 -98% in this study). IgGs from sera are also highly fucosylated (18, 19, 27, 39) . Unfortunately, the Lec13 cell line is not robust enough to consider as a production cell line, because the expression levels of the anti-HER2 Hu4D5 and anti-IgE HuE27 antibodies in this cell line were low compared with the standard CHO cells used. Treatment of fucosylated IgG with fucosidases (65) may be useful for generating enough afucosyl IgG to use for assays but might be impractical for production. Hence, a production cell line deficient in fucosylation of IgG remains a challenge.
